Cargando…
Neoadjuvant Rectal (NAR) Score: a New Surrogate Endpoint in Rectal Cancer Clinical Trials
The conduct of clinical trials in colorectal cancer has historically relied upon endpoints such as disease-free (DFS) or overall survival (OS). While ideal, these endpoints require long-term follow-up, thus contributing to a slow pace of scientific progress in clinical research. Identification of sh...
Autores principales: | George, Thomas J., Allegra, Carmen J., Yothers, Greg |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4550644/ https://www.ncbi.nlm.nih.gov/pubmed/26321890 http://dx.doi.org/10.1007/s11888-015-0285-2 |
Ejemplares similares
-
Exploration of Malignant Characteristics in Neoadjuvant Chemotherapy-Resistant Rectal Cancer, Focusing on Extramural Lesions
por: Kubota, Shunsuke, et al.
Publicado: (2023) -
Treatment Interval between Neoadjuvant Chemoradiotherapy and Surgery in Rectal Cancer Patients: A Population-Based Study
por: Rombouts, A. J. M., et al.
Publicado: (2016) -
Radiomics-Based Pretherapeutic Prediction of Non-response to Neoadjuvant Therapy in Locally Advanced Rectal Cancer
por: Zhou, Xuezhi, et al.
Publicado: (2019) -
Long-Term Outcomes of Local Excision Following Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer
por: D’Alimonte, Lucrezia, et al.
Publicado: (2020) -
The Pretreatment Systemic Inflammatory Response is an Important Determinant of Poor Pathologic Response for Patients Undergoing Neoadjuvant Therapy for Rectal Cancer
por: Dreyer, Stephan B., et al.
Publicado: (2016)